News Boehringer latest to axe Alzheimer's drug Company will trial BI 409306 in schizophrenia instead.
News Tysabri failure in stroke a setback for Biogen Biogen’s hopes that one of its established multiple sclerosis drugs might also help stroke sufferers have been dashed.
News Roche's MS drug Ocrevus priced in line with Novartis rival i... Drug likely to cost just under £10,000 per six-monthly injection.
News Roche's Ocrevus MS drug approved in EU Already a big hit in the US, Ocrevus set to make debut in EU.
News NHS funding for five MS drugs under threat NICE calls for further discounts on beta-interferons and Copaxone
News Bill Gates enters dementia research with $50m donation Fund is challenging prevailing 'amyloid hypothesis'
News Biogen, Denali pull Parkinson's drug after failed trial Biogen has stopped development of Denali-partnered Parkinson's disease candidate BIIB122, after it failed to move the needle in a phase 2b trial.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
